Skip to main content
. 2020 Aug 14;10:1426. doi: 10.3389/fonc.2020.01426

Figure 3.

Figure 3

Residual melanoma tumors upon MAPKi therapy exhibit L/L signature. The AMPK/HIF-1 signatures and TCA/glycolysis scores of BRAF-mutated tumor samples upon MAPKi treatment for the indicated time points. The RNA-Seq data are obtained from GEO with the series ID GSE75299. The red arrows denote the direction of the change of AMPK and HIF-1 activity of samples upon MAPKi treatment. The detailed information of the patients has been summarized in Supplementary Table 6.